Olivier Courbette1, Camille Aupiais2, Jérôme Viala1, Jean-Pierre Hugot1,3, Xavier Roblin4, Sophie Candon5, Baptiste Louveau2, Lucienne Chatenoud5, Christine Martinez-Vinson1. 1. Assistance Publique-Hôpitaux de Paris, Hôpital Robert Debré. 2. UMRS 1138 (CRC) and UMR 1123 (ECEVE), INSERM, University Paris-Diderot Sorbonne Paris-Cité. 3. Université Paris Diderot Sorbonne Paris-Cité; INSERM UMR1149; centre de recherche sur l'inflammation, Paris. 4. Department of Gastroenterology, University Hospital of Saint Etienne, Saint Etienne. 5. Université Paris Descartes, Sorbonne Paris Cité and INSERM U1151, CNRS UMR 8253, INEM Hôpital Necker-Enfants Malades, Paris, France.
Abstract
OBJECTIVE: Infliximab (IFX) is a frequent therapeutic option for Crohn disease (CD) patients. Early detection of responders to IFX is critical for the management of CD in order to avoid long-term exposure to the drug without benefit. This retrospective study aimed at analysing which early parameters recorded during the induction period are able to predict response to IFX during the maintenance period in pediatric CD. PATIENTS AND METHODS: Medical records of all CD patients ages from 2 to 18 years who received IFX at a tertiary IBD center were retrospectively analyzed. Children were classified in 3 groups according to their response at week 14 (W14) remission, clinical response or , no response. The factors recorded at W0, W2, and W6, which were associated with remission at W14 were analyzed using a logistic regression. RESULTS: Among the 111 patients included, 74.8% patients were responders to IFX at W14, including 38.7% in clinical remission and 36% with partial clinical response. Clinical remission at W14 was associated with normal growth (P < 0.01), and normal albuminemia (P = 0.01) at baseline, It was also associated with trough levels to IFX >8.3 μg/ml at week 6 (P < 0.01). CONCLUSION: Trough levels to IFX >8.3 μg/ml at week 6 are predictive of remission at W14 for luminal disease.
OBJECTIVE:Infliximab (IFX) is a frequent therapeutic option for Crohn disease (CD) patients. Early detection of responders to IFX is critical for the management of CD in order to avoid long-term exposure to the drug without benefit. This retrospective study aimed at analysing which early parameters recorded during the induction period are able to predict response to IFX during the maintenance period in pediatric CD. PATIENTS AND METHODS: Medical records of all CDpatients ages from 2 to 18 years who received IFX at a tertiary IBD center were retrospectively analyzed. Children were classified in 3 groups according to their response at week 14 (W14) remission, clinical response or , no response. The factors recorded at W0, W2, and W6, which were associated with remission at W14 were analyzed using a logistic regression. RESULTS: Among the 111 patients included, 74.8% patients were responders to IFX at W14, including 38.7% in clinical remission and 36% with partial clinical response. Clinical remission at W14 was associated with normal growth (P < 0.01), and normal albuminemia (P = 0.01) at baseline, It was also associated with trough levels to IFX >8.3 μg/ml at week 6 (P < 0.01). CONCLUSION: Trough levels to IFX >8.3 μg/ml at week 6 are predictive of remission at W14 for luminal disease.
Authors: Sara Salvador-Martín; Bartosz Kaczmarczyk; Rebeca Álvarez; Víctor Manuel Navas-López; Carmen Gallego-Fernández; Ana Moreno-Álvarez; Alfonso Solar-Boga; Cesar Sánchez; Mar Tolin; Marta Velasco; Rosana Muñoz-Codoceo; Alejandro Rodriguez-Martinez; Concepción A Vayo; Ferrán Bossacoma; Gemma Pujol-Muncunill; María J Fobelo; Antonio Millán-Jiménez; Lorena Magallares; Eva Martínez-Ojinaga; Inés Loverdos; Francisco J Eizaguirre; José A Blanca-García; Susana Clemente; Ruth García-Romero; Vicente Merino-Bohórquez; Rafael González de Caldas; Enrique Vázquez; Ana Dopazo; María Sanjurjo-Sáez; Luis A López-Fernández Journal: Pharmaceutics Date: 2021-01-08 Impact factor: 6.321
Authors: Sara Salvador-Martín; Irene Raposo-Gutiérrez; Víctor Manuel Navas-López; Carmen Gallego-Fernández; Ana Moreno-Álvarez; Alfonso Solar-Boga; Rosana Muñoz-Codoceo; Lorena Magallares; Eva Martínez-Ojinaga; María J Fobelo; Antonio Millán-Jiménez; Alejandro Rodriguez-Martinez; Concepción A Vayo; Cesar Sánchez; Mar Tolin; Ferrán Bossacoma; Gemma Pujol-Muncunill; Rafael González de Caldas; Inés Loverdos; José A Blanca-García; Oscar Segarra; Francisco J Eizaguirre; Ruth García-Romero; Vicente Merino-Bohórquez; María Sanjurjo-Sáez; Luis A López-Fernández Journal: Int J Mol Sci Date: 2020-05-09 Impact factor: 5.923